Choose a folder
Treatment patterns in the global DISCOVER population
The DISCOVER team is excited to announce the publication of an article assessing first- and second-line treatments in DISCOVER patients. The article, titled ‘Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: results from the global DISCOVER study programme’, was published in Diabetes, Obesity and Metabolism on 12 July 2019.
The study found that, overall, the most commonly used first-line treatment was metformin, prescribed either as a monotherapy (57.9%) or in combination with a sulphonylurea (14.6%). The most common combinations were those of metformin and a dipeptidyl peptidase-4 (DPP-4) inhibitor (25.1%) or metformin and a sulphonylurea (21.3%).
In patients who had been prescribed metformin as first-line monotherapy, the main second-line therapies were combinations of metformin and a DPP-4 inhibitor (32.8%) or metformin and a sulphonylurea (30.0%). Choice of second-line treatments varied greatly across regions (Figure). The use of new glucose-lowering agents, such as sodium–glucose co-transporter-2 inhibitors and glucagon-like peptide 1 receptor agonists, was particulary low in some regions (Figure). Both clinical factors, such as glycated haemoglobin level, and non-clinical factors, such as employment status and health insurance coverage, were associated with second-line treatment choice.
The full article is available to read and download free of charge here!
Figure. Second-line treatment choice in patients who received first-line metformin montherapy, overall and by DISCOVER study region.
DPP-4i; dipeptidyl peptidase-4 inhibitor; GLP-1 RA, glucagon-like peptide-1 receptor agonist;
SGLT-2i, sodium–glucose co-transporter-2 inhibitor; SU, sulphonylurea.